Crucell: Investors

Home | Contact | Search | Site Map

About Us

	Corporate Profile
	Share Information
	Financial Information
	Press Releases
	Event Calendar
	Presentations
	Shareholder Services
	Investor Relations Contact
	Crucell's press releases are available via an RSS feed. To add this RSS feed to your reader, right click on the RSS button, click "Copy Shortcut" and add the URL to your feed reader. If you are new to RSS, we suggest you read the Introduction to RSS article.

<< Back

Crucell to Webcast Presentation at the Needham & Company Biotech Conference

Leiden, The Netherlands, June 4, 2002 - PRNewswire-FirstCall via COMTEX/ -- Dutch antibody and vaccine company Crucell N.V. (Nasdaq: CRXL; Euronext) today announced that it will present at The Needham & Company First Annual Biotech Conference on Tuesday, June 4, 2002 at 2:00 p.m. EDT. The conference is being held at the Millennium Broadway Hotel in New York City, New York. Crucell's presentation will be webcast live for investors and available for replay for 60 days following the conference. The webcast can be accessed by going to http://www.twst.com/econf/mm/needham2/crxl.html.

About Crucell

Dutch biotechnology company Crucell discovers and develops antibody and vaccine products against cancer, inflammatory and infectious diseases.

The company licenses products to (bio)pharmaceutical companies for which it receives upfront and annual payments, milestones and royalties.

Crucell is currently developing antibodies against different types of cancer and has additional programs in inflammation, diabetes and cardiovascular diseases. Crucell will leverage its proprietary MAbstract(TM) technology to discover new targets and antibodies.

Crucell's CD 46 antibody against various types of cancers is licensed to Centocor, a Johnson & Johnson company. Crucell retains the commercial rights for Europe for this product.

Merck & Co. has obtained the exclusive rights to use Crucell's PER.C6(TM) human cell line for the production of the key adenoviral vector of its experimental HIV vaccine. Merck & Co. is currently conducting Phase I/II trials for this vaccine.

The company has furthermore developed a new flu vaccine production system, based on its patented human cell system PER.C6(TM). PER.C6(TM) is widely embraced by the industry for the production of viral vectors and vaccines.

Crucell shares trade on the NASDAQ and Euronext. Crucell is based in Leiden, The Netherlands. Crucell currently employs 180 people.